This research is for patients with Stage I-III HER2 positive breast cancer who are experiencing tummy problems from a type of cancer treatment called pertuzumab-based therapy. The study tests an investigational medication called rifaximin to see if it can help manage these issues.
Participants must be adults with HER2 positive breast cancer, planning to get pertuzumab-based treatment. They should not have certain health problems like heart issues, tummy diseases, or be pregnant. Participants will need to provide some samples like stool and urine for the study.
- The study lasts for about 5 treatment cycles, with each cycle taking 21 days.
- Participants may need to visit the research center multiple times for follow-ups and tests.
- Patients will be monitored for any side effects and changes in their condition.
This is an opportunity to help researchers understand how well the investigational medication works in managing tummy troubles caused by pertuzumab-based therapy.
How understandable was the trial content above?
Hard to understand
Easy to understand